Added to YB: 2026-03-10
Pitch date: 2026-03-07
NVO [neutral]
Novo Nordisk A/S
+11.05%
current return
Author Info
HatedMoats identifies hated moats. I buy companies when the market panics. Contrarian investor focused on quality, value & long-term growth. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.2T
Pitch Price
DKK 237.28
Price Target
74.00 (-72%)
Dividend
4.50%
EV/EBITDA
8.11
P/E
11.29
EV/Sales
4.07
Sector
Pharmaceuticals
Category
value
Novo Nordisk (NVO): Updated DCF Valuation
NVO (update): DCF revised down to DKK476/$74 (from $99) after 2026 trough: -9% rev decline, 42% EBIT margin, 7% WACC, 2% terminal growth. Stock at DKK248/$38.5 implies bear case (-13% rev, 36% margin, 8% WACC). Base case: 48% margin of safety, +92% upside. Deeply undervalued.
Read full article (10 min)